Abstract
Isoniazid (INH) has been a cornerstone of anti-tuberculosis therapy for nearly 70 years, yet the mechanisms behind its long-term side effects, including hepatotoxicity and potential carcinogenicity, have remained unclear. This study identifies a novel histone post-translational modification (PTM), lysine isonicotinylation ($K_{inic}$), directly induced by INH and its metabolites. We demonstrate that INH promotes the biosynthesis of isonicotinyl-CoA, which serves as a substrate for histone modification. Through mass spectrometry, 26 $K_{inic}$ sites were identified on histones in HepG2 cells. The modification is catalyzed by acetyltransferases CBP and p300 and removed by the deacetylase HDAC3. Functionally, $K_{inic}$ relaxes chromatin structure and activates the PI3K/Akt/mTOR signaling pathway via upregulation of PIK3R1, suggesting a molecular link between INH treatment and increased cancer risk.
Introduction
Isoniazid (INH) is a first-line medication for tuberculosis, valued for its efficacy but limited by significant side effects. While the metabolic pathways of INH are well-documented, its impact on the host's epigenetic landscape was previously unknown. This research explores whether INH can "hijack" cellular metabolic machinery to introduce synthetic epigenetic marks, specifically investigating the role of isonicotinyl-CoA in histone modification.
Identification of a Novel Histone Modification
Using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), researchers identified a unique mass shift of +105.0215 Da on lysine residues in HepG2 cells treated with INH. This shift corresponds to the addition of an isonicotinyl group. To validate this finding, a custom pan anti-$K_{inic}$ antibody was developed. Western blot analysis confirmed the presence of $K_{inic}$ across a wide range of human and insect cell lines, demonstrating that this modification is a widespread biological phenomenon when INH or its metabolites are present.
Enzymatic Regulation and Functional Impact
The study identified the "writers" and "erasers" of this new mark. The acetyltransferases CREB-binding protein (CBP) and p300 were found to catalyze the addition of the isonicotinyl group, while histone deacetylase 3 (HDAC3) acts as the primary deisonicotinylase.
Unlike smaller acyl modifications, $K_{inic}$ features a bulky pyridine ring. This structural change significantly alters chromatin dynamics. MNase sensitivity assays and RNA-seq analysis revealed that $K_{inic}$ promotes a more "open" chromatin state (euchromatin), facilitating the transcription of over 300 genes. Notably, the upregulation of the PIK3R1 gene activates the PI3K/Akt/mTOR pathway, a critical driver of cell proliferation and tumor growth.
Clinical Implications and Tumorigenicity
To assess the clinical significance of $K_{inic}$, researchers examined human tissue samples. Immunohistochemical (IHC) staining revealed varying levels of $K_{inic}$ across different normal human tissues, with notable concentrations in the oesophageal epithelium and fundic glands.
Furthermore, $K_{inic}$ levels were significantly elevated in several cancer types, including lung adenocarcinoma and thyroid carcinoma, compared to adjacent healthy tissues. This suggests that the accumulation of $K_{inic}$—whether through drug exposure or endogenous metabolic shifts—may contribute to oncogenesis.
Conclusion
The discovery of lysine isonicotinylation establishes a direct link between a widely used synthetic drug and the host's epigenetic code. By promoting chromatin relaxation and activating pro-growth signaling pathways, INH-induced $K_{inic}$ provides a plausible mechanism for the drug's long-term side effects and potential role in liver cancer. Future research is needed to identify the "reader" proteins that recognize this mark and to evaluate the broader implications for other pyridine-containing compounds.
Summary updated